EGFR and neoplasm: In both the PRIME and OPUS studies, a negative effect on efficacy was reported from combining an EGFR mAb with FOLFOX4 among patients whose tumours harboured a RAS mutation (Douillard et al, 2010, 2013; Bokemeyer et al, 2011, 2015).